ELSIE BIOTECHNOLOGIES
Live / Allowed — Fifth extension granted (statement of use) (as of 04 Aug 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 08 Aug 2022 filing date already counts against anyone who files later.
Record
- Serial number
- 97539845
- Mark type
- Word mark
- Filed
- 08 Aug 2022
- Published for opposition
- 19 Dec 2023
- Attorney of record
- Christopher M. Hanes
Goods and services
- Class 001 — Chemicals: Oligonucleotide compounds for use in the manufacture of pharmaceutical therapies
- Class 005 — Pharmaceuticals: Oligonucleotide compounds for use as pharmaceutical therapies prescribed or administered by a physician for the treatment of a wide variety of conditions and illnesses; Oligonucleotide delivery agents that facilitate delivery of a wide range of pharmaceutical therapies prescribed or administered by a physician; Oligonucleotide-based or -derived pharmaceuticals prescribed or administered by a physician for the treatment of a wide variety of conditions and illnesses; Pharmaceuticals prescribed or administered by a physician comprised of oligonucleotide compounds for the treatment of a wide variety of conditions and illnesses; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents prescribed or administered by a physician; drug delivery agents consisting of oligonucleotide compounds that facilitate delivery of a wide range of pharmaceuticals prescribed or administered by a physician
- Class 040 — Treatment of materials: Custom manufacture of oligonucleotides
- Class 042 — Scientific and technological services: Research and development of oligonucleotide compounds for use in pharmaceutical therapies; Research and development of oligonucleotide delivery agents for use in pharmaceutical therapies; Research and development of oligonucleotide-based or -derived pharmaceuticals; Research and development of pharmaceuticals comprised of oligonucleotide compounds; Research and development of oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents; Research and development of drug delivery agents consisting of oligonucleotide compounds
Owner
- Elsie Biotechnologies Inc., San Diego, CA, US
- Elsie Biotechnologies Inc., San Diego, CA, US
Prosecution history
- 04 Aug 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Aug 2026 — SOU EXTENSION 5 GRANTED
- 29 Jul 2026 — SOU EXTENSION 5 FILED
- 29 Jul 2026 — SOU TEAS EXTENSION RECEIVED
- 14 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Feb 2026 — SOU EXTENSION 4 GRANTED
- 05 Feb 2026 — SOU EXTENSION 4 FILED
- 05 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 04 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Nov 2025 — SOU EXTENSION 3 GRANTED
- 12 Aug 2025 — SOU EXTENSION 3 FILED
- 03 Nov 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 14 Aug 2025 — SOU EXTENSION RECEIVED WITH TEAS PETITION
- 14 Aug 2025 — NOTICE OF REVIVAL - E-MAILED
- 14 Aug 2025 — PETITION TO REVIVE-GRANTED